AgingResearch.NewsJoin free

Jade Biosciences

CompanyUnited States

Jade Biosciences develops 3 assets, the furthest in phase 3 (JADE101 in IgA nephropathy). Mostly antibody acting on TNFSF13; based in the United States.

3
Assets
Furthest stage
Phase 3
Raised
$260M
1
Trial
2
Signals

Pipeline

3

  • JADE101

    Blocks APRIL signaling to reduce antibody production, including pathogenic IgA.

    Phase 3, Antibody, TNFSF13, IgA nephropathy

  • JADE-001

    Blocks APRIL to reduce pathogenic IgA production and immune complex-mediated kidney damage.

    Preclinical, Antibody, TNFSF13, IgA nephropathy

  • JADE301

    Monospecific antibody targeting an undisclosed target.

    Stage not known, Antibody

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Funding rounds and grants3
  • Deals7
  • Signals8
  • Similar companies6

Intelligence